MedPath

tSMS in Essential Tremor

Phase 2
Completed
Conditions
Essential Tremor
Registration Number
NCT03780426
Lead Sponsor
Fundación de investigación HM
Brief Summary

This is randomized double-blind study to study the hypothesis that transcranial static magnetic field stimulation of the primary motor cortex improves tremor in patients with essential tremor. Half of the patients will receive tSMS of the left hemisphere and the other half of the right hemisphere.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Essential tremor
Exclusion Criteria
  • MRI-incompatible metal objects in the body (e.g. cardiac pacemakers)
  • other main neuropsychiatric co-morbidity
  • pregnancy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Change from baseline in postural tremor amplitude in the hand contralateral to hemispheren that received tSMS treatment compared to the hand contralateral to the hemisphere that received sham treatment, as measured by accelerometry.Immediately after treatment compared baseline
Secondary Outcome Measures
NameTimeMethod
Change from baseline in tremor frequency, as measured by accelerometry.Immediately after treatment and 15 minutes after treatment compared baseline.
Change from baseline in postural tremor amplitude 15 minutes after treatment, as measured by accelerometry.15 minutes after treatment compared to baseline
Change from baseline in rest tremor amplitude, as measured by accelerometry.Immediately after treatment and 15 minutes after treatment compared baseline.
Change from baseline in the Clinical Rating Scale for Tremor part B (drawing)5 minutes after treatment and 20 minutes after treatment compared to baseline

Trial Locations

Locations (1)

CINAC, Hospital Universitario Puerta del Sur

🇪🇸

Móstoles, Madrid, Spain

CINAC, Hospital Universitario Puerta del Sur
🇪🇸Móstoles, Madrid, Spain

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.